Literature DB >> 29341068

Analysis of hypo- and hypermagnesemia in an intensive care unit cohort.

M Broman1, F Hansson1, B Klarin1.   

Abstract

INTRODUCTION: The aim of this study was to evaluate if magnesium deviations correlate with higher 180 day overall mortality or increased morbidity, compared to controls.
METHODS: We conducted a retrospective study on 5369 patients with 22,003 magnesium values treated at the Adult Intensive Care Unit at Skåne University Hospital, Lund, Sweden during 2006-2014. The patients were retrospectively divided into a control group with only normal magnesium values 0.7-1.0 mmol/l, and three study groups; hypomagnesemic; Mg2+ < 0.7 mmol/l, hypermagnesemic; Mg2+ > 1.0 mmol/l and an unstable mixed group showing both hypo/hypermagnesemia. Gender, age, disease severity represented by maximum organ system SOFA score, renal SOFA score, lowest potassium value and diagnoses classes were included in a Cox hazard model in order to adjust for confounding factors, with time to death in the first 180 days from the ICU admission as outcome.
RESULTS: The hypermagnesemic study group and the mixed group showed increased hazard ratios for mortality; 1.4 (CI 98.3% 1.2, 1.6, P < 0.0001) and 2.1 (CI 98.3% 1.2, 2.8, P < 0.0001) respectively, compared to controls, while the hypomagnesemic group did not reach significance. In addition, patients in the hypermagnesemic and the mixed groups are older, more ill with significantly higher EMR and SOFA scores and show significantly longer ventilator times and ICU stays, compared to controls.
CONCLUSIONS: Patients with magnesium deviations are more ill compared to patients with explicitly normal magnesium values throughout the ICU stay. Cox analysis suggests that the magnesium deviation itself might have an impact on mortality.
© 2018 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29341068     DOI: 10.1111/aas.13061

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

1.  Abnormal magnesium levels and their impact on death and acute kidney injury in critically ill children.

Authors:  Hikaru Morooka; Akihito Tanaka; Daisuke Kasugai; Masayuki Ozaki; Atsushi Numaguchi; Shoichi Maruyama
Journal:  Pediatr Nephrol       Date:  2021-10-26       Impact factor: 3.714

2.  Association of magnesium abnormalities at intensive care unit admission with kidney outcomes and mortality: a prospective cohort study.

Authors:  Heitor S Ribeiro; Emmanuel A Burdmann; Edilene A Vieira; Mateus L Ferreira; Aparecido P Ferreira; Antônio J Inda-Filho
Journal:  Clin Exp Nephrol       Date:  2022-06-27       Impact factor: 2.617

Review 3.  Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials.

Authors:  Juan R Muñoz-Castañeda; María V Pendón-Ruiz de Mier; Mariano Rodríguez; María E Rodríguez-Ortiz
Journal:  Int J Mol Sci       Date:  2018-02-27       Impact factor: 5.923

4.  Serum magnesium, mortality and disease progression in chronic kidney disease.

Authors:  Rami Azem; Remy Daou; Elias Bassil; Eva Maria Anvari; Jonathan J Taliercio; Susana Arrigain; Jesse D Schold; Tushar Vachharajani; Joseph Nally; Georges N Na Khoul
Journal:  BMC Nephrol       Date:  2020-02-12       Impact factor: 2.388

5.  A Novel U-Shaped Association Between Serum Magnesium on Admission and 28-Day In-hospital All-Cause Mortality in the Pediatric Intensive Care Unit.

Authors:  Chao Yan Yue; Chun Yi Zhang; Zhen Ling Huang; Chun Mei Ying
Journal:  Front Nutr       Date:  2022-02-21

6.  Initial Serum Magnesium Level Is Associated with Mortality Risk in Traumatic Brain Injury Patients.

Authors:  Ruoran Wang; Min He; Jianguo Xu
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

7.  Cost-effectiveness of the TherMax blood warmer during continuous renal replacement therapy.

Authors:  Michael J Blackowicz; Max Bell; Jorge Echeverri; Kai Harenski; Marcus E Broman
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.